AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE)
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE) Seeking Alpha
Covered in this story
Analyst targets on AbbVie
- Citi: $244 → $260 by Jul 2027 · Neutral via GuruFocus
- UBS: $248 → $260 by Jul 2027 · Neutral via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 50 stories mentioning AbbVie, the earliest published 15 May 2026.
Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.